Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ONCT Stock Summary
Top 10 Correlated ETFs
ONCT
In the News
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2023 Results Conference Call March 7, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to Oncternal's Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $3.11 per share versus the Zacks Consensus Estimate of a loss of $3.09. This compares to loss of $4 per share a year ago.
Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Securities Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions].
Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer & Company Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.23 per share a year ago.
Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrnes - Northland Capital Markets Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to the Oncternal Therapeutics First Quarter 2023 Financial Results Call. [Operator Instructions] As a reminder, this conference will be recorded.
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.20 per share a year ago.
Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
Penny Stocks To Buy? 7 Under $1 To Watch This Week
Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.